Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) today issued the following statement ahead of the Food and Drug Administration’s (FDA) expected action to grant traditional approval to Leqembi, a drug to treat Alzheimer’s: 

“The Centers for Medicare and Medicaid Services (CMS) should already be covering key Alzheimer’s treatments that have been cleared under the FDA’s accelerated approval pathway, which already meet the FDA’s gold standard of safety and effectiveness. However, should FDA grant traditional approval to these drugs after reviewing confirmatory trial data, as is being reported and was recommended unanimously by the FDA Advisory Committee, there will be no excuses for CMS to effectively deny coverage to Americans in need.” 

READ MORE: 

Rodgers, Smith: Biden Admin Doubles Down on Restricting Medicare Coverage for Seniors 

Chair Rodgers Applauds VA Coverage of Alzheimer’s Drug, Urges CMS to Reconsider